- Home
- PSNYW vs TARA Comparison
PSNYW vs TARA Comparison
Compare PSNYW & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNYW | TARA |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Sweden | United States |
| Employees | 2547 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 292.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PSNYW | TARA |
|---|---|---|
| Price | $3.21 | $5.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 6.3K | ★ 588.2K |
| Earning Date | 03-06-2025 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,034,261,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $2.77 |
| 52 Week High | $7.50 | $7.82 |
Technical Indicators
Market Signals| Indicator | PSNYW | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 48.57 |
| Support Level | $2.88 | $4.92 |
| Resistance Level | $3.99 | $5.47 |
| Average True Range (ATR) | 0.34 | 0.27 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 28.44 | 42.86 |
Price Performance
Historical ComparisonAbout PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.